A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
NCT00207025
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Tumors
Interventions
DRUG:
BMS-275183
Sponsor
Bristol-Myers Squibb